{"id":799404,"date":"2025-01-10T01:03:10","date_gmt":"2025-01-10T06:03:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/"},"modified":"2025-01-10T01:03:10","modified_gmt":"2025-01-10T06:03:10","slug":"innate-pharma-announces-transformative-strategy-to-accelerate-growth","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/","title":{"rendered":"Innate Pharma Announces Transformative Strategy to Accelerate Growth"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwleftsingle { border-left: solid black 1pt }\n.bwlistcircle { list-style-type: circle }\n.bwlistdisc { list-style-type: disc }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwrightsingle { border-right: solid black 1pt }\n.bwsinglebottom { border-bottom: solid black 1pt }\n.bwtablemarginb { margin-bottom: 10px }\n.bwtopsingle { border-top: solid black 1pt }\n.bwuline { text-decoration: underline }\n.bwvertalignt { vertical-align: top }\n.bwwidth100 { width: 100% }\n.bwwidth30 { width: 30% }\n.bwwidth40 { width: 40% }\n.bwwidth70 { width: 70% }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\n\u00a0<b>Innate Pharma Announces Transformative Strategy to Accelerate Growth<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n\u00a0<b>Strategy anchored on early clinical development of proprietary assets with single-agent potential:<\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li><b>Drive innovation with first-in-class ANKET<sup>\u00ae<\/sup> NK-cell engager Platform<\/b><\/li>\n<li><b>Accelerate development of differentiated Antibody-Drug Conjugates<\/b><\/li>\n<li><b>Advance current late-stage assets through partnerships<\/b><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>MARSEILLE, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:<\/p>\n<p>\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide.<\/p>\n<p>\n&#8220;<i>Our updated strategy underscores Innate Pharma\u2019s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide,<\/i>&#8221; said <b>Jonathan Dickinson, Chief Executive Officer of Innate Pharma<\/b>. &#8220;<i>With a focus on our ANKET<sup>\u00ae<\/sup> platform and ADC programs, we are poised to redefine the landscape of immunotherapy, addressing unmet needs in oncology and autoimmune diseases. This roadmap reflects our steadfast commitment to advancing science, strengthening partnerships, and maximizing value for patients and shareholders alike as we look toward a brighter future in immuno-oncology.<\/i>&#8221;<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwpadl0 bwtopsingle bwleftsingle bwrightsingle bwwidth100\" rowspan=\"1\" colspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwleftsingle bwrightsingle bwwidth100\" style=\"height:24px\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\nJonathan Dickinson will represent the Company in a session at the 43rd Annual J.P. Morgan Healthcare Conference scheduled Tuesday, January 14, 2025 from 11:15 &#8211; 11:55 am PST.<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwleftsingle bwrightsingle bwwidth100\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwalignc bwleftsingle bwrightsingle bwwidth100\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\nA live webcast of the session will be available at the following link:<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjpmorgan.metameetings.net%2Fevents%2Fhealthcare25%2Fsessions%2F58707-innate-pharma%2Fwebcast%3Fgpu_only%3Dtrue%26kiosk%3Dtrue&amp;esheet=54176218&amp;newsitemid=20250109242503&amp;lan=en-US&amp;anchor=https%3A%2F%2Fjpmorgan.metameetings.net%2Fevents%2Fhealthcare25%2Fsessions%2F58707-innate-pharma%2Fwebcast%3Fgpu_only%3Dtrue%26amp%3Bkiosk%3Dtrue&amp;index=1&amp;md5=dbe613240717d176aa8d9810fef23155\">https:\/\/jpmorgan.metameetings.net\/events\/healthcare25\/sessions\/58707-innate-pharma\/webcast?gpu_only=true&amp;kiosk=true<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwwidth100\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Three Pillars of Growth<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Drive innovation with first-in-class ANKET<sup>\u00ae<\/sup> Platform:<\/b> A new era in NK cell therapeutics is at the heart of Innate Pharma\u2019s strategy, based around its validated, proprietary Antibody-based NK Cell Engager Therapeutics (ANKET<sup>\u00ae<\/sup>) platform. This cutting-edge technology with anticipated applications in hematologic malignancies, solid tumors, and autoimmune diseases leverages the advantages of harnessing NK cell effector functions and can create proliferation of NK cells. By advancing its clinical pipeline, Innate aims to exploit therapeutic possibilities in oncology and autoimmune diseases. IPH6501, Innate\u2019s proprietary ANKET<sup>\u00ae<\/sup> is currently being investigated in a Phase 1\/2 study in patients with CD20-expressing non-Hodgkin\u2019s Lymphoma.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Accelerate development of differentiated Antibody-Drug Conjugates (ADCs):<\/b> Innate Pharma is advancing its ADC programs to develop differentiated and highly targeted treatments that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. IPH4502, Innate\u2019s lead ADC, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4, is being investigated in a Phase 1 trial in patients with advanced solid tumors.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>Advance current late-stage assets through partnerships: <\/b>Partnerships will continue to play a critical role in the Company\u2019s strategy, for broader impact with Innate\u2019s established antibody assets, including lacutamab and monalizumab. Innate is actively seeking a partner to progress lacutamab for patients with advanced forms of T cell lymphomas. Monalizumab, currently in a Phase 3 trial PACIFIC-9 led by AstraZeneca in non-small cell lung cancer, will see readouts by end of 2026. By entrusting these promising therapies to strategic partners, Innate ensures their ongoing development and potential commercialization, maximizing their therapeutic potential and reach.\n<\/li>\n<\/ul>\n<p>\nWith this multi-faceted strategy, Innate Pharma believes it is positioned to accelerate its growth trajectory and reinforce its leadership in the immuno-oncology space. The Company\u2019s robust scientific expertise, strategic collaborations, and focus on patient outcomes create a strong foundation for success.<\/p>\n<p><b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET<sup>\u00ae<\/sup> (<b>A<\/b>ntibody-based <b>NK<\/b> cell <b>E<\/b>ngager <b>T<\/b>herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).<\/p>\n<p>\nInnate\u2019s portfolio includes several ANKET<sup>\u00ae<\/sup> drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.<\/p>\n<p>\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=54176218&amp;newsitemid=20250109242503&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=2&amp;md5=903f94b905ef1222009f01cea4f53265\">www.innate-pharma.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=54176218&amp;newsitemid=20250109242503&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=cd9c7be5d598a71671ee94639d1b0cba\">LinkedIn<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FInnatePharma&amp;esheet=54176218&amp;newsitemid=20250109242503&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=b6eb1674c9ffc0c6eed53e6c2fffe9a2\">X<\/a>.<\/p>\n<p><b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth40\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth30\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\"><b>ISIN code<br \/>\n<\/b><br \/><b>Ticker code<br \/>\n<\/b><br \/><b>LEI<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth70\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cpotential,\u201d \u201cexpect\u201d \u201cshould,\u201d \u201cwill,\u201d or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s reliance on third parties to manufacture its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=54176218&amp;newsitemid=20250109242503&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=5&amp;md5=c417572d0ae9f1b39e9a38e634dc1fed\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n<p>\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250109242503\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250109242503\/en\/<\/a><\/span><\/p>\n<p><b>For additional information, please contact:<br \/>\n<\/b><\/p>\n<p><b><span class=\"bwuline\">Investors<\/p>\n<p><\/span>Innate Pharma<br \/>\n<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Henry.wheeler@innate-pharma.fr\">Henry.wheeler@innate-pharma.fr<\/a><\/p>\n<p><b><span class=\"bwuline\">Media Relations<br \/>\n<br \/><\/span><\/b><br \/><b>NewCap<br \/>\n<\/b><br \/>Arthur Rouill\u00e9<br \/>\n<br \/>Tel.: +33 (0)1 44 71 00 15<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:innate@newcap.eu\">innate@newcap.eu<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Europe United States North America France California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250109242503\/en\/1245155\/3\/INNATEvertnoirDS.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0Innate Pharma Announces Transformative Strategy to Accelerate Growth \u00a0Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET\u00ae NK-cell engager Platform Accelerate development of differentiated Antibody-Drug Conjugates Advance current late-stage assets through partnerships MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. &#8220;Our updated strategy underscores Innate Pharma\u2019s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide,&#8221; said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. &#8220;With a focus on our &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate Pharma Announces Transformative Strategy to Accelerate Growth&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799404","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Announces Transformative Strategy to Accelerate Growth - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Announces Transformative Strategy to Accelerate Growth - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u00a0Innate Pharma Announces Transformative Strategy to Accelerate Growth \u00a0Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET\u00ae NK-cell engager Platform Accelerate development of differentiated Antibody-Drug Conjugates Advance current late-stage assets through partnerships MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. &#8220;Our updated strategy underscores Innate Pharma\u2019s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide,&#8221; said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. &#8220;With a focus on our &hellip; Continue reading &quot;Innate Pharma Announces Transformative Strategy to Accelerate Growth&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T06:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma Announces Transformative Strategy to Accelerate Growth\",\"datePublished\":\"2025-01-10T06:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/\"},\"wordCount\":1231,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/\",\"name\":\"Innate Pharma Announces Transformative Strategy to Accelerate Growth - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-01-10T06:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Announces Transformative Strategy to Accelerate Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Announces Transformative Strategy to Accelerate Growth - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Announces Transformative Strategy to Accelerate Growth - Market Newsdesk","og_description":"\u00a0Innate Pharma Announces Transformative Strategy to Accelerate Growth \u00a0Strategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET\u00ae NK-cell engager Platform Accelerate development of differentiated Antibody-Drug Conjugates Advance current late-stage assets through partnerships MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211; Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key pillars designed to drive sustainable growth, foster innovation, and deliver transformative therapies to patients worldwide. &#8220;Our updated strategy underscores Innate Pharma\u2019s unwavering dedication to innovation, collaboration, and delivering transformative therapies for patients worldwide,&#8221; said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. &#8220;With a focus on our &hellip; Continue reading \"Innate Pharma Announces Transformative Strategy to Accelerate Growth\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-10T06:03:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma Announces Transformative Strategy to Accelerate Growth","datePublished":"2025-01-10T06:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/"},"wordCount":1231,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/","name":"Innate Pharma Announces Transformative Strategy to Accelerate Growth - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-01-10T06:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250109242503r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-announces-transformative-strategy-to-accelerate-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Announces Transformative Strategy to Accelerate Growth"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799404"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799404\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}